The Part D Redesign

The Medicare course covered the beneficiary-facing side of the Part D redesign: a $615 deductible, 25 percent coinsurance, and a hard $2,100 out-of-pocket cap in 2026. This lesson covers what it did to the parties bearing the risk, which is where the behavioral consequences live.

The risk reassignment

Capping beneficiary exposure did not make the cost disappear. It moved.

Medicare’s reinsurance payments to plans now “subsidize 20% of brand-name drug spending and 40% of generic drug spending, down from 80% in previous years.” Manufacturers also pay rebates when drug prices rise faster than inflation.

That is a large reallocation. A plan that previously ceded 80 percent of catastrophic spending to Medicare now retains most of it.

What follows from that

The finance course would predict the response, and it is what has happened: an entity that suddenly retains catastrophic risk manages it.

• Tighter formularies, since the plan now bears the consequence of covering an expensive drug generously.
• More utilization management on high-cost drugs, including prior authorization and step therapy.
• Harder rebate negotiation, since net cost matters more when the plan keeps the exposure.
• Premium pressure on stand-alone drug plans, whose economics changed most.

None of this is misconduct. It is the predictable behavior of an organization given more risk, and it was foreseeable at the time the policy was designed.

Reading the trade honestly

Who gained	Who absorbed it
Beneficiaries with high drug costs, who now face a hard $2,100 ceiling	Plans, which retain most catastrophic spending
Beneficiaries who previously owed 5 percent coinsurance with no ceiling	Manufacturers, through inflation rebates and redesigned liability

The beneficiary protection is real and substantial. Before the redesign, a patient on a high-cost specialty drug faced 5 percent coinsurance indefinitely, which for an expensive therapy meant thousands of dollars a year with no end.

The access friction is also real. A patient protected by the cap may face more prior authorization reaching the drug in the first place.

Worth remembering: this is the clearest recent example of a principle that applies to every arrangement in this curriculum. You cannot cap what one party pays without deciding who else absorbs it, and whoever absorbs it will manage it. Policy discussions that celebrate the cap without naming the consequence, or that condemn the tightened formularies without naming the protection, are each describing one half of a single design decision. Holding both halves is what the evaluation course asked for, and it is the only honest way to judge whether the trade was worth making.

Key takeaways

• The 2026 Part D benefit is a $615 deductible, 25 percent coinsurance, and a hard $2,100 out-of-pocket cap.
• Medicare reinsurance in the catastrophic phase fell from 80 percent to 20 percent for brands and 40 percent for generics.
• Plans responded with tighter formularies, more utilization management, and harder rebate negotiation.
• The beneficiary protection and the access friction are two consequences of one design decision.

Sources

• KFF, A Current Snapshot of the Medicare Part D Prescription Drug Benefit (opens in a new tab)
• KFF, Key Facts About Medicare Spending Trends and Projections from the 2026 Medicare Trustees Report (opens in a new tab)